Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence
Authors:
- Robert Douglas BruceRBRobert Douglas Bruce
- Frederick L. AlticeFAFrederick L. Altice
- 19 January 2011
- journal article
- research article
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 37 (1) , 1-11
Abstract
Background: Psychiatric comorbidities among opioid-dependent patients are common. Many medications used to treat both conditions are metabolized through complimentary cytochrome P450 isoenzymes. When medication-assisted treatment for opioid dependence is concurrently used with psychotropic medications, problematic pharmacokinetic drug interactions may occur. Methods: We reviewed relevant English language articles identified through the MedLine, Scopus, and Embase databases from 1950 to December 2009 using the specific generic names of medications and keywords such as pharmacokinetics and drug interactions with buprenorphine, methadone, and naltrexone. Selected references from these articles were reviewed. Additionally, a review was conducted of abstracts and conference proceedings from national and international meetings from 1990 to 2009. A total of 60 studies were identified and reviewed. Results: Clinical case series and carefully controlled pharmacokinetic interaction studies have been conducted between methadone, buprenorphine, or naltrexone and some psychoactive medications. Important pharmacokinetic drug interactions have been demonstrated within each class of medications affecting either methadone and buprenorphine or psychoactive drugs. Few studies, however, have been conducted with naltrexone. Conclusions: Several interactions between methadone, buprenorphine, or naltrexone and psychoactive medications are described and may have important clinical consequences. To optimize care, clinicians must be alerted to these interactions.Keywords
This publication has 122 references indexed in Scilit:
- Utilization, price, and spending trends for antidepressants in the US Medicaid programResearch in Social and Administrative Pharmacy, 2008
- A Community-Based Evaluation of Sudden Death Associated with Therapeutic Levels of MethadoneThe American Journal of Medicine, 2008
- Tricyclic antidepressant pharmacology and therapeutic drug interactions updatedBritish Journal of Pharmacology, 2007
- Pharmacokinetic Interactions between Buprenorphine and Antiretroviral MedicationsClinical Infectious Diseases, 2006
- Methadone-Induced Respiratory Depression After Discontinuing Carbamazepine AdministrationJournal of Pain and Symptom Management, 2006
- Interactions on Mixing Diazepam With Methadone or Buprenorphine in Maintenance PatientsJournal of Clinical Psychopharmacology, 2006
- Impact of methadone treatment on cardiac repolarization and conduction in opioid usersThe American Journal of Cardiology, 2005
- The effect of sertraline and environmental context on treating depression and illicit substance use among methadone maintained opiate dependent patients: a controlled clinical trialDrug and Alcohol Dependence, 2004
- Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomesLife Sciences, 1997
- Buprenorphine, benzodiazepines and prolonged respiratory depressionAnaesthesia, 1987